ClinicalTrials.gg
RecruitingNCT06939582RIOMUpdated Apr 29, 2025

Hydroxychloroquine Sulfate Tablets for Radiation-induced Oral Mucositis

A Phase 1/2 interventional study of Hydroxychloroquine Sulfate Tablets and Placebo in Radiation-induced Oral Mucositis, sponsored by Xingchen Peng. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by Xingchen Peng · Phase 1/2, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled Dec 2024, registered Apr 2025).
  • Started Dec 2024; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
158
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 31 studies in Stomatitis with a site in China — 13 open to participants now, 13 under way, 2 of them phase 3. Stomatitis · China.

Planned enrollment
13th of 29
158 · median 138
Started
2024
with 3 others
Phase 1/2
2 of 31
1 open now
Primary completion
2025-06
later than 4 of 12 live
Registered
22nd of 31
by date

Among the 31 studies in Stomatitis with a site in China, this one is the 13th largest by planned enrollment of the 29 interventional ones that give a count, is one of 4 that started in 2024, is one of 2 in phase 1/2, reaches primary completion later than 4 of the 12 other live ones, and was the 22nd registered.

Stomatitis

307 studies on the registry are indexed under Stomatitis; 74 are open to participants now.

Browse Stomatitis studies →

Open to participants now

13 of the 31 studies in Stomatitis with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 45 Stomatitis studies recruiting now, 20 (44%) set no upper age limit and 21 (47%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Stomatitis with a site in China, or all of them as a file.
02

Study summary

Evaluate the safety, tolerance and efficacy of hydroxychloroquine sulfate tablets the prevention and treatment of oral mucositis and dysgeusia in patients undergoing radiotherapy

03

Conditions studied

  • Radiation-induced Oral Mucositis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with non- head and neck malignant tumors
  • Aged 18-80 years
  • performance status of ≤2
  • Planning to receive definitive RT or postoperative adjuvant RT
  • Normal liver, kidney and bone marrow function
  • Sign

Exclusion criteria

Exclusion Criteria:

  • Those who are known to be allergic to 4-aminoquinoline compounds or have more serious allergic constitution
  • Had a history of head and neck radiotherapy
  • Patients with non head and neck parts in the radiotherapy area
  • Poor oral hygiene or severe periodontitis
  • Suffering from severe kidney disease, severe cardiovascular disease, myasthenia gravis, Parkinson's disease or epilepsy
  • Recently taking or taking diuretics or other drugs known to interact with hydroxychloroquine sulfate tablets
  • Retinopathy
  • Other patients (combined with any serious other diseases) who the investigator believes are not suitable for participation in this study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
158 participants (estimated)

Study arms

  • Placebo comparator
    Control group

    use the placebo

    Other: Placebo

  • Experimental
    trial group

    use the hydroxychloroquine sulfate tablets

    Drug: Hydroxychloroquine Sulfate Tablets

Interventions

06

What researchers measure

Primary outcomes

  1. the WHO grade of RIOM

    use the WHO Oral Toxicity Scale to evaluate the WHO grade of RIOM. WHO O grade: no representation of RIOM; WHO 1 grade: soreness and erythema; WHO 2 grade: erythema, ulcers and ability to eat solids; WHO 3 grade: ulcers, requiring liquid diet; WHO 4 grade: alimentation not possible. The higher scores mean a worse outcome.

    Time frame: From the start of radiotherapy to 8 weeks after completion of radiotherapy

07

Study locations

1 of 1 sites recruiting
  • Department of Radiation Oncology
    Chengdu, Sichuan 610000, China
    Recruiting
08

References and documents

Publications

  • Schrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166. doi: 10.1038/s41584-020-0372-x. Epub 2020 Feb 7. PubMed 32034323 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Jun 2025, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2025
First posted
Apr 23, 2025
StartActual
Dec 22, 2024
Primary completionEst.
Jun 1, 2025
CompletionEst.
Jun 20, 2025
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06939582
Lead sponsor
Xingchen Peng
Responsible party
Xingchen Peng (Department of Radiation Oncology, Clinical Professor,West China Hospital, West China Hospital) — Sponsor-investigator
First posted
Apr 23, 2025
Start date
Dec 22, 2024
Primary completion
Jun 1, 2025 (estimated)
Completion
Jun 20, 2025 (estimated)
Last update
Apr 29, 2025

Study contacts

Peng xingchen Professor
Contact
pxx2014@scu.edu.cn
+86 1880606753

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hydroxychloroquine

Start the discussion